Enovis Corp
ENOV
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
149.6% downsideOvervalued by 149.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.48 Billion |
|---|---|
| Enterprise Value | $1.54 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20.86 |
| Beta | 1.5 |
| Outstanding Shares | 56,792,000 |
Return
| Return on Equity | -82.10% |
|---|---|
| Return on Assets | -31.64% |
| Return on Invested Capital | -36.75% |
Valuation & Multiples
| P/E Ratio | -1.29 |
|---|---|
| PEG | 1.53 |
| Price to Sales | 0.85 |
| Price to Book Ratio | 1.01 |
| Enterprise Value to Revenue | 0.85 |
| Enterprise Value to EBIT | -1.3 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 2.51% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.46%▼ 117.65% |
|---|---|
| Total Invested | $5.43M▼ 99.64% |
| Investors Holding | 9▼ 252.00% |
ESG Score
No data
About Enovis Corp
15,400 employees
CEO: Matthew Trerotola Colfax Corporation is a leading diversified technology company that provides specialty medical technologies and fabrication technology products and services to customers around the world, principally under the DJO and ESAB brands. Colfax...
Relevant Senate Committees
Oversees Medicare and Medicaid reimbursement rates, which are fundamental to the profitability of Enovis's orthopedic products, and manages trade/tariff policies affecting manufacturing costs.
This committee oversees the FDA, which regulates the approval and safety of Enovis's medical devices, and handles labor laws affecting its manufacturing workforce.
Enovis relies on an aggressive acquisition strategy and significant intellectual property; this committee oversees antitrust enforcement and patent law, both of which are critical to its business model.
The VA is a major purchaser of orthopedic and rehabilitative medical devices (DJO brand). Funding and procurement decisions here directly impact Enovis's revenue.